Evidence map›Paper›PMID 39651117›Full record

ArticlebioRxiv : the preprint server for biology2024

Diverse priming outcomes under conditions of very rare precursor B cells.

Patrick J Madden, Ester Marina-Zárate, Kristen A Rodrigues, Jon M Steichen, Monolina Shil, Kaiyuan Ni, Katarzyna Kaczmarek Michaels, Laura Maiorino, Amit A Upadhyay, Swati Saha and 31 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

41 authors.

Patrick J MaddenCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Ester Marina-ZárateCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Kristen A RodriguesKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Jon M SteichenConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
Monolina ShilCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Kaiyuan NiKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Katarzyna Kaczmarek MichaelsKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Laura MaiorinoKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Amit A UpadhyayEmory National Primate Research Center and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
Swati SahaDepartment of Biochemistry and Molecular Genetics, University of Louisville School of Medicine, Louisville, KY, USA.
Arpan PradhanEmory National Primate Research Center and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
Oleksandr KalyuzhinyConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
Alessia LiguoriConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
Paul G LopezCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Ivy PhungCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Nicole PhelpsConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
Erik GeorgesonConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
Nushin AlaviConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
Michael KubitzConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
Danny LuConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
Saman EskandarzadehConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
Amanda MetzEmory National Primate Research Center and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
Oscar L RodriguezDepartment of Biochemistry and Molecular Genetics, University of Louisville School of Medicine, Louisville, KY, USA.
Kaitlyn ShieldsDepartment of Biochemistry and Molecular Genetics, University of Louisville School of Medicine, Louisville, KY, USA.
Steven SchultzeDepartment of Biochemistry and Molecular Genetics, University of Louisville School of Medicine, Louisville, KY, USA.
Melissa L SmithDepartment of Biochemistry and Molecular Genetics, University of Louisville School of Medicine, Louisville, KY, USA.
Brandon S HealyEmory National Primate Research Center and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
Deuk LimEmory National Primate Research Center and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
Vanessa R LewisEmory National Primate Research Center and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
Elana Ben-AkivaKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
William PinneyKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Justin GregoryKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Shuhao XiaoKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Diane G CarnathanEmory National Primate Research Center and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
Sudhir Pai KasturiEmory National Primate Research Center and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
Corey T WatsonDepartment of Biochemistry and Molecular Genetics, University of Louisville School of Medicine, Louisville, KY, USA.
Steven E BosingerEmory National Primate Research Center and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
Guido SilvestriEmory National Primate Research Center and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
William R SchiefConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
Darrell J IrvineConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
Shane CrottyCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.ORCID 0000-0002-6484-6262

Funding

Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6M
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Illumina NovaSeq 6000 High Throughput DNA Sequencer for Emory UniversityS10OD026799 · OD · EMORY UNIVERSITY · PI BOSINGER, STEVEN EDWARD · 2019 to 2019
$985k
NovaSeq5000 High Throughput SequencerS10OD025052 · OD · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SEUMOIS, GREGORY · 2018 to 2018
$832k
NIAID NIH HHS UM1 AI144462NIH HHS P51 OD011132NIH HHS S10 OD025052NIH HHS S10 OD026799
6 · The paper itself

Abstract

Rare B cells can have special pathogen-recognition features giving them the potential to make outsized contributions to protective immunity. However, rare naive B cells infrequently participate in immune responses. We investigated how germline-targeting vaccine antigen delivery and adjuvant selection affect priming of exceptionally rare BG18-like HIV broadly neutralizing antibody-precursor B cells (~1 in 50 million) in non-human primates. Only escalating dose (ED) priming immunization using the saponin adjuvant SMNP elicited detectable BG18-like cells in germinal centers (GCs). All groups had strong GC responses, but only ED+SMNP and bolus+SMNP induced BG18-like memory B cells in >50% of animals. One group had vaccine-specific GC responses equivalent to ED+SMNP, but BG18-like memory B cells were rarely detected. Following homologous boosting, BG18-like memory B cells were more frequent in a bolus priming group, but had lower somatic hypermutation and affinities. This outcome was inversely associated with post-prime antibody titers, suggesting antibody feedback can significantly influence rare precursor B cell responses.

Identifiers

PMID39651117
PMCPMC11623517

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.